The authors reply: Letter on: "Myostatin inhibition in combination with antisense oligonucleotide therapy improves outcomes in spinal muscular atrophy" by Zhou et al

J Cachexia Sarcopenia Muscle. 2020 Oct;11(5):1379-1380. doi: 10.1002/jcsm.12608. Epub 2020 Jul 23.

Authors

Haiyan Zhou^{1

2}, Francesco Muntoni^{2

3}

Affiliations

¹ Genetics and Genomic Medicine Research and Teaching Department, Great Ormond Street Institute of Child Health, University College London, London, UK.
² NIHR Great Ormond Street Hospital Biomedical Research Centre, London, UK.
³ The Dubowitz Neuromuscular Centre, Developmental Neurosciences Research and Teaching Department, Great Ormond Street Institute of Child Health, University College London, London, UK.

No abstract available

Keywords: Combinatorial therapy; Spinal muscular atrophy; Survival motor neuron protein.

Publication types

Letter
Research Support, Non-U.S. Gov't
Comment

MeSH terms

Humans
Muscular Atrophy, Spinal* / genetics
Muscular Atrophy, Spinal* / therapy
Myostatin*
Oligonucleotides, Antisense / therapeutic use

Substances

Myostatin
Oligonucleotides, Antisense

Grants and funding